The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury

Nanjing First Hospital, Nanjing Medical University101 enrolled

Overview

To testify the prevention of Erythropoietin on cardiac surgery associated-acute kidney injury, and trying to provide evidence for protecting the renal function and improving the prognosis for patients after cardiac surgery.

Patients meet the inclusion criteria and agree to sign an informed consent will be randomly assigned into the control group or erythropoietin group.Interventions will be applied 1 day(24hrs) before the cardiac surgery. Blood and Urine samples will be collected after the surgery. By using the criterion given by KDIGO2012 and testing the biomarkers for acute kidney injury, we hope to find out if there is an association between erythropoietin administration and the occurence of acute kidney injury.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

101

Conditions

Acute Kidney Injury Cardiac Disease Surgery

Interventions

ErythropoietinDRUG

10000 IU erythropoietin, subcutaneous injection

0.9% sodium chlorideDRUG

0.9% sodium chloride 1ml, subcutaneous injection

cardiac surgeryPROCEDURE

included valve, coronary artery bypass graft or surgery for congenital heart diseases

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Preoperative hemoglobin\<130g/L; 2. Surgery: valve, coronary artery bypass graft or surgery for congenital heart diseases; 3. Volunteers with informed consent. Exclusion Criteria: 1. Patients combined with infection; 2. Patients with end-stage renal disease and undergoing renal replacement therapy 3. Patients with the history of thromboembolism; 4. Patients with malignant tumor and undergoing chemotherapy; 5. Patients with unmanageable hypertension (systolic pressure\>200 mmHg or diastolic pressure\>110mmHg); 6. Patients allergic to erythropoietin; 7. Patients injected erythropoietin within 2 weeks.

Locations (1)

Nanjing First Hospital

Nanjing, Jiangsu, China

Outcomes

Primary Outcomes

Number of Participants With Acute Kidney Injury

Occurrence of acute kidney injury according to KDIGO guideline

Time frame: 7 days

Secondary Outcomes

Number of Participants With Renal Replacement Therapy

suffering from severe acute kidney injury(3.0 times baseline OR Increase in serum creatinine to ≥4.0 mg/dl (≥353.6 mmol/l)), olignuria≥24 hours or anuria≥12 hours.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.